Rocket Pharmaceuticals(US:RCKT)2025-11-06 21:04Financial Performance - Rocket Pharmaceuticals reported a net loss of $50.3 million, or $0.45 per share, for Q3 2025, compared to a net loss of $66.7 million, or $0.71 per share, for Q3 2024[9]. - Total operating expenses for Q3 2025 were $52.2 million, down from $69.4 million in Q3 2024[15]. - The company incurred approximately $3.3 million in restructuring expenses in 2025[8]. Research and Development - Research and development expenses decreased to $34.1 million in Q3 2025 from $42.3 million in Q3 2024, reflecting a reduction of $8.2 million[9]. - The Phase 2 trial of RP-A501 for Danon disease is set to resume in the first half of 2026, with three additional patients to be treated at a recalibrated dose[4]. Administrative Expenses - General and administrative expenses were $18.4 million for Q3 2025, down from $27.1 million in Q3 2024, a decrease of $8.7 million[9]. Cash and Assets - Cash, cash equivalents, and investments totaled approximately $222.8 million as of September 30, 2025, expected to fund operations into Q2 2027[9]. - Rocket's total assets were $368.0 million as of September 30, 2025, compared to $527.7 million at the end of 2024[15]. Regulatory Updates - The FDA has set a PDUFA date of March 28, 2026, for KRESLADI™ for the treatment of severe leukocyte adhesion deficiency-I (LAD-I)[4]. Leadership Changes - Rocket Pharmaceuticals appointed Dr. Syed Rizvi as Chief Medical Officer, bringing over 20 years of experience in cell and gene therapy[5].